These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35246429)

  • 21. Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review.
    Teragaki M; Tanaka M; Yamamoto H; Watanabe T; Takeoka J; Fukumi A; Maeda K; Takami Y; Saita H; Iwanari S; Ikeda M; Takeoka H
    CEN Case Rep; 2024 Feb; 13(1):53-58. PubMed ID: 37244881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal change disease following vaccination for SARS-CoV-2.
    Mancianti N; Guarnieri A; Tripodi S; Salvo DP; Garosi G
    J Nephrol; 2021 Aug; 34(4):1039-1040. PubMed ID: 34143368
    [No Abstract]   [Full Text] [Related]  

  • 23. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
    Holzworth A; Couchot P; Cruz-Knight W; Brucculeri M
    Kidney Int; 2021 Aug; 100(2):463-464. PubMed ID: 34048824
    [No Abstract]   [Full Text] [Related]  

  • 24. Acute-onset dacryoadenitis following immunisation with mRNA COVID-19 vaccine.
    Murphy T; Raheem Abu Shanab A; Kang K; Lyons CJ
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35256374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.
    Dooling K; Gargano JW; Moulia D; Wallace M; Rosenblum HG; Blain AE; Hadler SC; Plumb ID; Moline H; Gerstein J; Collins JP; Godfrey M; Campos-Outcalt D; Morgan RL; Brooks O; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1344-1348. PubMed ID: 34555007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical Presentation of Erythema Nodosum Following Pfizer-BioNTech COVID-19 Vaccine.
    Alzoabi N; Alqahtani J; Algamdi B; Almutairi M; Alratroot J; Alkhaldi S; Alqahtani S; Alakloby O
    Med Arch; 2022 Feb; 76(1):72-74. PubMed ID: 35422564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021.
    Lutrick K; Rivers P; Yoo YM; Grant L; Hollister J; Jovel K; Khan S; Lowe A; Baccam Z; Hanson H; Olsho LEW; Fowlkes A; Caban-Martinez AJ; Porter C; Yoon S; Meece J; Gaglani M; Burns J; Mayo Lamberte J; Nakayima Miiro F; Bissonnette A; LeClair L; Kutty PK; Romine JK; Stefanski E; Edwards LJ; Ellingson K; Gerald JK; Bedrick EJ; Madhivanan P; Krupp K; Gerald LB; Thompson M; Burgess JL
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1761-1765. PubMed ID: 34968373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [
    Skawran S; Gennari AG; Dittli M; Treyer V; Muehlematter UJ; Maurer A; Burger IA; Mader C; Messerli O; Grünig H; Gebhard C; Huellner MW; Curioni-Fontecedro A; Berger C; Messerli M
    Eur Radiol; 2022 Jan; 32(1):508-516. PubMed ID: 34156552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report.
    Lemoine C; Padilla C; Krampe N; Doerfler S; Morgenlander A; Thiel B; Aggarwal R
    Clin Rheumatol; 2022 May; 41(5):1597-1601. PubMed ID: 35294664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Herpes zoster in a patient with first onset of childhood nephrotic syndrome following the second SARS-CoV-2 vaccination.
    Nakashima K; Horinouchi T; Tanaka Y; Ichikawa Y; Nozu K
    CEN Case Rep; 2024 Aug; 13(4):306-307. PubMed ID: 37695475
    [No Abstract]   [Full Text] [Related]  

  • 31. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al.
    Scorza FA; Finsterer J
    Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005
    [No Abstract]   [Full Text] [Related]  

  • 32. In brief: Pfizer/BioNTech COVID-19 vaccine authorized for children 5-11 years old.
    Med Lett Drugs Ther; 2021 Nov; 63(1638):185. PubMed ID: 35085214
    [No Abstract]   [Full Text] [Related]  

  • 33. Nephrotic syndrome following COVID-19 vaccination: a systematic review.
    Parikh C; Upadhyay H; Patel S; Sundararajan R; Shah D; Anand A; Baraskar B; Bhatt T; Verma D; Agrawal S; Mittal A; Gupta S
    J Nephrol; 2023 Dec; 36(9):2431-2440. PubMed ID: 37505405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations in Pfizer-BioNTech COVID-19 vaccine preparation in clinic: Quality vs quantity.
    Jin CH; Tran LM; Rivero CJ; Childs RR
    Am J Health Syst Pharm; 2022 Feb; 79(5):325-327. PubMed ID: 34634098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2.
    Schroeder JW; Gamba C; Toniato A; ; Rongioletti F
    Clin Dermatol; 2022; 40(5):591-594. PubMed ID: 35550918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine.
    Ryu DW; Lim EY; Cho AH
    Neurol Sci; 2022 Feb; 43(2):771-773. PubMed ID: 34811599
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
    Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 Updates: Pfizer-BioNTech COVID-19 vaccine.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35134045
    [No Abstract]   [Full Text] [Related]  

  • 40. Relapse of Idiopathic Nephrotic Syndrome After SARS-CoV-2 Vaccination: Two Case Reports.
    Güngör T; Yazılıtaş F; Kargın Çakıcı E; Karakaya D; Bülbül M
    J Paediatr Child Health; 2022 May; 58(5):939-940. PubMed ID: 35416332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.